Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03013218 · ClinicalTrials.gov registry record · Phase 1

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

A Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by ALX Oncology.

Completed
Registry status
Phase 1
Development phase
174
Enrollment target
10
Study locations

NCT03013218 is a Phase 1 study of Solid Tumor and Advanced Cancer that has completed, run by ALX Oncology. The registered enrollment target is 174 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (21% lower). The trial reports 10 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03013218, a Phase 1 study of Solid Tumor and Advanced Cancer, has completed, sponsored by ALX Oncology.

COMPLETED
Registry status
Phase 1
Development phase
174 participants
Enrollment target
10
Study locations

Study Summary

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

Conditions Studied

Solid Tumor Advanced Cancer Metastatic Cancer NonHodgkin Lymphoma

Interventions

  • DRUG Pembrolizumab
  • DRUG Trastuzumab
  • DRUG Rituximab
  • DRUG Evorpacept (ALX148)
  • DRUG Ramucirumab + Paclitaxel

Study Locations (10)

Other

  • Seoul National University Bundang Hospital - Seongnam
  • Samsung Medical Center - Seoul
  • Seoul National University Hospital - Seoul
  • Severance Hospital, Yonsei University - Seoul

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Colorado

  • University of Colorado Denver - Denver

Connecticut

  • Yale University - New Haven

Michigan

  • START-Midwest - Grand Rapids

Washington

  • Seattle Cancer Care Alliance - Seattle

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2017-02-03
Est. Completion 2025-07-08
Phase Phase 1

Sponsor

ALX Oncology

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03013218

The ClinicalTrials.gov registry entry for NCT03013218 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (21% lower). The listed sponsor is ALX Oncology, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT03013218 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Other, Massachusetts, Colorado.

Frequently Asked Questions

What is clinical trial NCT03013218 about?

NCT03013218 is a clinical study titled "A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)". A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

What is the current status of trial NCT03013218?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2017-02-03. Estimated completion is 2025-07-08.

What conditions does trial NCT03013218 study?

This clinical trial studies the following conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, NonHodgkin Lymphoma.

What interventions are being tested in trial NCT03013218?

The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Rituximab (DRUG), Evorpacept (ALX148) (DRUG), Ramucirumab + Paclitaxel (DRUG).

Who is sponsoring clinical trial NCT03013218?

This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03013218 being conducted?

This trial has 10 study locations across Colorado, Connecticut, Massachusetts, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Advanced Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.